FDA offers solution for generic approvals during label changes; AbbVie to buy back shares;

@FiercePharma: Shire's Vyvanse tops $1B as more generics challenge Adderall. Report | Follow @FiercePharma

@EricPFierce: Mylan currently the focus of a hot rumor for picking up the sterile injectables unit of India's Strides Arcolab. News | Follow @EricPFierce

@AlisonBFierce: A promising new vaccine--administered as a nasal spray--is shrinking head and neck tumors. More | Follow @AlisonBFierce

> The FDA has come out with a plan for approving generic drugs even when the drug they are copying is in the midst of a label change. Story

> New spin-off AbbVie ($ABBV) says it will buy back $1.5 billion in shares over the next couple of years. News

> A federal court has upheld two patents held by Cephalon, which is now owned by Teva ($TEVA), related to the cancer drug Fentora, turning back a generic challenge by Actavis ($ACT). Report

> After years of appeals, Sanofi ($SNY) has won a tax case in India that tried to nail it for capital gains taxes when it acquired Shantha in 2009. Article

Medical Device News

 @FierceMedDev: Cohera snags $17M to support TissuGlu. News | Follow @FierceMedDev

 @MarkHFierce: Weight loss devices never go out of style. BAROnova secured a $27.3M Series C for its contribution to the space. More | Follow @MarkHFierce

 @DamianFierce: St. Jude is studying whether renal denervation can treat heart attack and stroke in addition to hypertension. Press release | Follow @DamianFierce

> Acquisitions help boost Alere's 2012 Q4 revenue. Item

> J&J braces international market for more metal hip problems. Article

> Second Sight scores victory with FDA nod for retinal prosthesis. News

Biotech News

 @FierceBiotech: Still trending: The 25 most influential people in biopharma today - 2013. Special Report | Follow @FierceBiotech

@JohnCFierce: Mega-mergers are back (expect 1-2 big deals in biopharma this year). News | Follow @JohnCFierce

@RyanMFierce: Japan takes lead in trialing a human stem cell therapy. Story | Follow @RyanMFierce

> GSK's Slaoui talks up 'innovative' late-stage pipeline as regulatory reviews loom. Article

> Biotech benefits from 'breakthrough' guess for its cancer med partnered with J&J. News

> Blog: AbbVie slams brakes on cancer drug trials after patient death. Report

And Finally... After several years of quiet among prescription sleep aids, Purdue Pharma has issued a wake up call to the category with an ad campaign featuring an adorably memorable anthropomorphic lightbulb. Item

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.